Physician profile
Mark Conliffe
NPI 1417243999
$75,197.14
in general payments reported to CMS, 2019-2025
18 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $229 · 2021: $297 · 2022: $182 · 2023: $361 · 2024: $52.29 · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $74K · Food and Beverage: $314 · Travel and Lodging: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $73,750.00 |
| Food and Beverage | $313.61 |
| Travel and Lodging | $260.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $73,777.73 | 2025 | |
| Spr Therapeutics, INC | $455.78 | 2020-2023 | Sprint Pns System |
| Abbott Laboratories | $324.72 | 2021-2023 | Proclaim |
| Ferring Pharmaceuticals INC. | $145.08 | 2019-2025 | Euflexxa |
| Medical Device Business Services, INC. | $89.82 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $85.29 | 2022-2025 | Zilretta, Exparel, Iovera |
| Pacira Therapeutics, INC. | $63.52 | 2020-2021 | |
| Depuy Synthes Sales INC. | $52.68 | 2019-2025 | Monovisc |
| Bioventus LLC | $36.68 | 2019-2022 | |
| Mimedx Group, INC. | $30.30 | 2024 | |
| Stimwave Technologies Incorporated | $30.27 | 2020-2022 | |
| Reprise Biomedical, INC. | $22.56 | 2025 | Miro3d |
| Grt US Holding, INC. | $16.98 | 2022 | |
| Horizon Therapeutics Plc | $16.03 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.31 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthogenrx INC. | $12.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.94 | 2019 | |
| Fidia Pharma USA INC. | $10.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Conliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.